Kamada Ltd. KMDA announced that the FDA has acknowledged the path forward for commencing a phase III study on the inhaled Alpha-1 Antitrypsin (Inhaled AAT) product, which is being developed for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results